Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.

@article{Sumida2014SuccessfulEO,
  title={Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.},
  author={Hayakazu Sumida and Yoshihide Asano and Zenshiro Tamaki and Naohiko Aozasa and Takashi Taniguchi and Takehiro Takahashi and Tetsuo Toyama and Yohei Ichimura and Shinji Noda and Kaname Akamata and Miki Miyazaki and Yoshihiro Kuwano and Koichi Yanaba and Shinichi Sato},
  journal={The Journal of dermatology},
  year={2014},
  volume={41 5},
  pages={418-20}
}
Previous studies have demonstrated that B cells play critical roles in autoimmune disorders including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). However, the effectiveness of rituximab (RTX), a chimeric anti-CD20 antibody, for SSc-associated interstitial lung disease (ILD) or SLE disease activity remains controversial. We herein report an SSc patient with severely progressed ILD and concomitant SLE treated by two cycles of RTX at baseline and half a year later. This… CONTINUE READING